COVID-19: Findings in nuclear medicine from head to toe

Clin Imaging. 2023 Jul:99:10-18. doi: 10.1016/j.clinimag.2023.04.003. Epub 2023 Apr 8.

Abstract

COVID-19 is a multisystemic disease, and hence its potential manifestations on nuclear medicine imaging can extend beyond the lung. Therefore, it is important for the nuclear medicine physician to recognize these manifestations in the clinic. While FDG-PET/CT is not indicated routinely in COVID-19 evaluation, its unique capability to provide a functional and anatomical assessment of the entire body means that it can be a powerful tool to monitor acute, subacute, and long-term effects of COVID-19. Single-photon scintigraphy is routinely used to assess conditions such as pulmonary embolism, cardiac ischemia, and thyroiditis, and COVID-19 may present in these studies. The most common nuclear imaging finding of COVID-19 vaccination to date is hypermetabolic axillary lymphadenopathy. This may pose important diagnostic and management dilemmas in oncologic patients, particularly those with malignancies where the axilla constitutes a lymphatic drainage area. This article aims to summarize the relevant literature published since the beginning of the pandemic on the intersection between COVID-19 and nuclear medicine.

Keywords: COVID-19; Nuclear medicine; PET-CT; SARS-CoV-2; Vaccination.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Fluorodeoxyglucose F18
  • Humans
  • Nuclear Medicine*
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radionuclide Imaging
  • Toes

Substances

  • COVID-19 Vaccines
  • Fluorodeoxyglucose F18